Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2

Cancer Immunology Immunotherapy

Volumn 42, Issue 4, 1996, Pages 221-230

  Ehrke, M Jane ^a   Verstovšek, Srdan ^a   Zaleskis, Gintaras ^a   Ho, Richard L X ^a   Ujházy, Peter ^a   Maccubbin, Darbie L ^a   Mihich, Enrico ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CD44; CD8 memory; chemoimmunotherapy; immunochemotherapy; senescence

Indexed keywords

CD8 ANTIGEN; DOXORUBICIN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; T CELL LYMPHOMA; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; SENSITIVITY AND SPECIFICITY; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; THYMUS GLAND;

EID: 0029953959     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050274     Document Type: Article

References (27)

1. Agus DB, Surh CD, Sprent J (1991) Reentry of T cells to the adult thymus is restricted to activated T cells. J Exp Med 173: 1039
2. Arbar AN, Borthwick N, Salmon M, Gombert W, Bofill M, Shamsadeen N, Pilling D, Pett S, Grundy JE, Janossy G (1993) The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med 178: 427
3. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Pitz J (1991) Extended continuous infusion of low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 9: 2110
4. Ehrke MJ, Maccubbin D, Ho RLX, Verstovsek S, Ujhazy P, Mihich E (1990) Therapeutically effective combinations of tumor necrosis factor with Adriamycin in murine syngeneic tumor models. Proc Am Assoc Cancer Res 31: 294
5. Fuji H, Mihich E (1975) Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res 35: 946
6. + cells. PhD dissertation, SUNY at Buffalo
7. Ho RLX, Maccubbin D, Ujhazy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ (1993) Immunological responses critical to the therapeutic effects of Adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol Res 5: 363
8. Ho RLX, Maccubbin D, Zaleskis G, Krawczyk C, Wing K, Mihich E, Ehrke MJ (1993) Development of a safe and effective Adriamycin plus interleukin 2 therapy against both Adriamycin-sensitive and -resistant lymphomas. Oncol Res 5: 373
9. + T-cell memory determined by clonal burst size. Nature 369: 652
10. Kitano M, Mihich E, Pressman D (1972) Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res 32: 181
11. Krawzcyk C, Verstovsek S, Ujhazy P, Maccubbin D, Ehrke MJ (1995) Protective specific immunity induced by cyclophosphamide plus TNF-α combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 40: 347
12. Lau LL, Jamieson BD, Somasundaram T, Ahmed R (1994) Cytotoxic T-cell memory without antigen. Nature 369: 648
13. Linton PJ, Decker DJ, Klinman NR (1989) Primary antibody-forming cells and secondary B cells are generated from separate precursor cell populations. Cell 59: 1049
14. Maccubbin D, Mace K, Ehrke MJ, Mihich E (1989) Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res 49: 4216
15. Maccubbin D, Wing K, Mace KF, Ho RLX, Ehrke MJ, Mihich E (1992) Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 52: 3572
16. Mihich E (1962) Host defense mechanisms in the regression of Sarcoma 180 in pyridoxine-deficient mice. Cancer Res 22: 218
17. Mihich E (1971) Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. Natl Cancer Inst 34: 90
18. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409
19. + T cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res 49: 4597
20. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM (1993) Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362: 758
21. Sprent J (1994) T and B memory cells. Cell 76: 315
22. Sprent J, Tough DF (1994) Lymphocyte life-span and memory. Science 265: 1395
23. Ujhazy P, Chen Y-E, Fredericks W, Ho RLX, Mihich E, Baker RM, Ehrke MJ (1990) The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model. Cancer Commun 2: 181
24. Ujhazy P, Maccubbin D, Eppolito C, Mihich E, Ehrke MJ (1994) TNFα potentiation of the lymphokine-activated killer response of murine thymus cells. Lymphokine Cytokine Res 13: 99
25. Yin X-M, Vitetta ES (1992) The lineage relationship between virgin and memory B cells. Int Immunol 6: 691
26. Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E (1994) Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol 46: 901
27. Zaleskis G, Ho RLX, Diegelman P, Maccubbin D, Ujhazy P, Mihich E, Ehrke MJ (1994) Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol Res 6: 183